Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT06928090
Enrolling by invitation Observational

Efficacy and Safety of DTG/3TC in Treatment-naïve HIV-1 Infected Patients

NCT06928090 · tracked via the Priya Life Science South Korea tracker
Sponsor
Chungnam National University Hospital
Phase
Observational
Started
2025-01-24
Last updated
2025-04-15

Condition(s) studied

HIV

Investigational drug(s) / intervention(s)

DTG + 3TC FDC

DTG + 3TC FDC: None(Non-interventional, retrospective chart review, single-arm study )

Study summary

Non-interventional, retrospective, single arm study of individuals who have initiated a DTG/3TC regimen. Medical chart will be reviewed by the investigators. Naive subjects will be identified by the clinic database as having initiated DTG/3TC.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * HIV-1 diagnosis * Prescribed DTG/3TC alone to manage HIV-1 infection as initial antiretroviral treatment at the study centers Exclusion Criteria: * HIV-2 diagnosis * Previous antiretroviral treatment

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Chungnam National University Hospital, 282 Munwha-ro Daejeon South Korea

More Chungnam National University Hospital trials in South Korea

Drug Response Testing and Repurposing Using Glioblastoma Organoid Recruiting
Effect of Essential Aminoacid Supplementation and Exercise on Skeletal Muscle Function in Hemodialysis Patients Recruiting
Prediction of Delayed Cognitive Impairment in Cardiac Arrest Survivors With Good Neurological Outcomes Enrolling by invitation
Biliary Complication Rates in Living Donor Liver Transplantation: a Retrospective Comparative Study of Stent Versus Non-Stent Groups Active, not recruiting
Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06928090 on ClinicalTrials.gov ↗ ← All trials in South Korea